Continuous infusion of low-dose topotecan: Pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer

Anti-Cancer Drugs

Volumn 9, Issue 5, 1998, Pages 411-418

  Herben, Virginie M M ^a,b   Ten Bokkel Huinink, Wim W ^a   Schot, Margaret E ^a   Hudson, Ian ^c   Beijnen, Jos H ^a,b  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Continuous infusion; Pharmacokinetics; Topotecan

Indexed keywords

TOPOTECAN;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; FATIGUE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARCINOMA, SMALL CELL; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; THROMBOCYTOPENIA; TOPOTECAN; TREATMENT OUTCOME; VOMITING;

EID: 0031814967     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199806000-00007     Document Type: Article

References (19)

1. Hsiang Y-H, Hertzberg R, Hecht S, et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14873-5.
2. Hsiang Y-H, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer camptothecin. Cancer Res 1988; 48: 1722-6.
3. Chen AY, Liu LF. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994; 34: 191-218.
4. Burris 3rd HA, Hanauske AR, Johnson RK, et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units. J Natl Cancer Inst 1992; 84: 1816-20.
5. Hochster H, Liebes L, Sorich J, et al. Increasing cleavable complex formation in peripheral blood lymphocytes with increasing topotecan infusion duration - a rationale for prolonged administration of camptothecins. In: 6th Conf on DNA Topoisomerases in Therapy, Amsterdam 1993: 88.
6. Hochster H, Liebes L, Speyer J, et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 1994; 12: 553-9.
7. SmithKline Beecham Pharma. Data on file.
8. Oken MM, Creech RH, Tormey DC. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
10. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990; 8: 147-59.
11. Rosing H, Doyle E, Davies BE, Beijnen JH. High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. J Chrom B 1995; 668: 107-11.
12. Rosing H, Herben VMM, Van Zomeren DM, et al. Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan. Cancer Chemother Pharmacol 1997; 39: 498-504.
13. Holford NHG, Sheiner LB. Kinetics of pharmacologic response. Pharmacol Ther 1982; 16: 143-66.
14. Creemers GJ, Eckardt JR, Verweij J, et al. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 1997; 15: 1087-93.
15. O'Reilly S, Rowinsky E, Slichenmyer W, et al. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. J Natl Cancer Inst 1996; 88: 817-23.
16. O'Reilly S, Rowinsky E, Slichenmyer W, et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996; 14: 3062-73.
17. Topotecan investigators brochure. SmithKline Beecham Pharmaceuticals, King of Prussia, PA 1994.
18. Herben VMM, Ten Bokkel Huinink WW, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996; 31: 85-102.
19. Saltz L, Sirott M, Young C, et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 1993; 85: 1499-507.